.png)
SummaryThere is no European pharmaceutical price. There are national systems that regulate different points of the same supply chain, publish different figures, and read each other through reference baskets. Understanding how the systems differ is less a matter of memorising 30 sets of rules than of recognising a small number of structural choices that each country makes.
From manufacturer to patient, the same positions exist everywhere:
Ex-factory price, what the manufacturer receives. Wholesale or pharmacy purchase price, what the pharmacy pays. Retail price, what is charged at the counter. Plus tax, at a rate that ranges from 2.1 percent in France to double digits elsewhere.
What differs is which of those positions a country regulates and which it publishes. Those two choices are not the same, and confusing them is the most common error in cross-country work.
Regime one: the manufacturer price is regulated. The authority sets, approves or is notified of the ex-factory price, and the levels above it follow from statutory margins. Belgium, Poland and Romania sit here, and in all three the manufacturer price is not only regulated but published.
Regime two: a downstream level is regulated. The authority sets the pharmacy purchase price or a maximum retail price, and the manufacturer level is not published at all. The Nordic countries sit here: Denmark publishes the pharmacy purchase price, Sweden the purchase and retail price, Norway maximum prices at both levels.
A third pattern cuts across both: countries that publish a gross consumer price from which everything else must be reconstructed. France and Spain are the clearest cases.
The practical consequence is stark. In regime one you read a number. In regime two and in the consumer price countries you compute one, using national margin rules, tax rates and sometimes a foreign substitute assumption, and the result is an estimate that has to be labelled.
| Country | Published level | Manufacturer price |
|---|---|---|
| Belgium | Ex-factory | Published |
| Poland | Manufacturer plus three further levels | Published |
| Romania | Manufacturer, wholesale, retail | Published |
| Italy | Retail for outpatient, ex-factory for hospital | Published for the hospital list |
| Germany | Manufacturer level, with negotiated amounts visible | Visible |
| France | Gross consumer price | Derived, numerically |
| Spain | Consumer price including tax | Derived from a legal band table |
| Denmark | Pharmacy purchase price | Estimated |
| Sweden | Purchase and retail price | Estimated |
| Finland | Wholesale and consumer price | Estimated |
| Norway | Maximum purchase and retail price | No factor exists |
| Netherlands | Consumer price, licence bound | Disputed factor |
| Austria | Sickness fund price free, manufacturer level licensed | Licensed |
| Switzerland | Ex-factory and public price | Published for listed products |
Fourteen countries, four different answers to the same question. That table is the reason a European price comparison needs a normalisation layer before it needs a chart.
Where a country regulates a downstream level, the route back to the manufacturer runs through trade margins, and those margins come in four structures across Europe.
Two rules govern any of them. Fixed components come off before percentage rates, and the band of a scale is selected by a specific price, which has to be established rather than assumed. For the Finnish scale the selling price reading is continuous at every band edge, largest jump 0.0032 euro, while the other reading jumps by up to 12.73 euro. That continuity test is the evidence, not a preference.
Even with the right level and the right margin rule, two national prices describe different objects unless the packs match. European sources handle that very differently.
Belgium and Poland publish a structured pack quantity. Norway publishes a GTIN. France's national code happens to be a valid GTIN across all 20,900 packs. Spain, Italy and Romania leave the pack size in free text, and Ireland's price file carries a code that matches nothing outside its own system.
For a comparison project that variation, rather than the pricing rules, usually sets the schedule. The rules are public and finite. The matching is per country and open ended.
Price regulation and reimbursement decisions are related and not identical.
Most countries regulate prices only for the reimbursed segment. Products outside it are usually freely priced and usually unpublished, which is why nearly every national file in Europe covers a subset rather than a market. Poland states it most plainly: non reimbursed medicines have free prices and are not published officially anywhere.
Reimbursement systems themselves differ along familiar lines. Some group therapeutically comparable products and fund up to a reference level, as Germany does with its fixed reimbursement amount and Spain does with homogeneous groups. Some assess added benefit and negotiate an amount, as Germany does after its benefit assessment. Since January 2025 the clinical part of that assessment is increasingly shared across the European Union through the joint clinical assessment, while the pricing decision stays national.
Is there a European drug price? No. There are national regulated figures at different points of the chain, plus a shared habit of reading each other.
Can I compare them? Yes, after normalising level, tax, pack and date, and with the result labelled as list price based.
Which country should I start with? The ones that publish the manufacturer price, because they need no derivation and give you a reference against which derivations elsewhere can be checked. Belgium and Poland are the obvious first two, with the Italian hospital list close behind.
Two historical forces explain most of the variation.
Countries that built their systems around a national health service tend to regulate what the service pays, which is a downstream level. Countries that built theirs around social insurance with a private distribution chain tend to regulate the manufacturer price and let statutory margins do the rest.
On top of that sits external reference pricing, applied in 29 of 31 countries we examined, which pushes national levels towards each other without harmonising the mechanisms. The result is convergence in outcome and persistent divergence in method, which is exactly the combination that makes European price data hard to work with.
Not a single number per country. A comparison that survives scrutiny carries, for every value: the country, the price level, the date, the source, whether the figure is published or derived, and the coverage of the underlying file.
That sounds heavy until you consider the alternative. A table of national prices without those fields cannot be reproduced, cannot be audited, and will be read as evidence of what health systems pay, which it is not.
European pharmaceutical pricing is not one system with national variations, it is a set of national systems that regulate different points of the same chain and read each other's published results. A few countries publish the manufacturer price directly. Most publish something further downstream, from which the manufacturer level has to be derived through statutory margins, tax rates and occasionally a borrowed assumption. Knowing which of those situations you are in, per country, is the whole of the work.
Related reading: European Drug Pricing Database: how cross-border prices work and Pharma pricing Germany: how the system works, plus external reference pricing in Europe, wholesale and pharmacy margins and list price vs net price.
pharmazie.com is the consolidated pharmaceutical data platform by DACON Datenbank Consulting GmbH that bundles 25+ specialist databases into a single search, exclusively for healthcare professionals. Price coverage focuses on the DACH region and a number of further EU countries, with more countries following in the coming months.
